Anyone who has sat through a post-surgery cancer consultation knows the question that hangs in the room: what are the odds it comes back? On October 8, the U.S. Food and Drug Administration gave doctors and families a much better answer.
The agency approved atezolizumab (Tecentriq, made by Genentech) together with standard chemotherapy as an after-surgery treatment for patients with Stage III mismatch repair deficient (dMMR) colon cancer. The approval covers adults and children aged two and older. A subcutaneous version, Tecentriq Hybreza, was also cleared for patients 12 and up – meaning eligible patients can get the immunotherapy as an under-the-skin injection rather than a longer IV infusion.
The numbers behind the approval
Context matters here. Roughly one in four colon cancers is diagnosed at Stage III, and nearly a third of those patients see their cancer return within five years. This is the first immunotherapy-based regimen ever approved for this setting, and Genentech expects it to become the new standard of care.
The decision rests on the Phase 3 ATOMIC trial, published in The New England Journal of Medicine. The study enrolled 711 adults and one pediatric patient with Stage III dMMR colon cancer after complete surgical removal of the tumor. One group received atezolizumab plus the standard mFOLFOX6 chemotherapy regimen (oxaliplatin, leucovorin, and fluorouracil) for 12 cycles, followed by atezolizumab alone for six months. The other group received chemotherapy alone for 12 cycles.
The headline result: the combination cut the risk of recurrence or death by 50 percent (hazard ratio 0.50, p=0.0001). At a median follow-up of about 41 months, three-year disease-free survival stood at 86.3 percent with the combination versus 76.2 percent with chemotherapy alone. The benefit held across node stage, tumor stage, and tumor location, and in a per-protocol analysis of 600 patients. Frank A. Sinicrope of the Mayo Clinic served as the U.S. principal investigator.
Why these particular tumors respond
Mismatch repair is the cell’s proofreading system – it fixes mistakes made when DNA is copied. When it is deficient, mutations stack up quickly. The tumor ends up looking strange to the immune system, covered in abnormal proteins that flag it as something wrong. Atezolizumab, a PD-L1 inhibitor, works by releasing the brakes on the immune response. In tumors already bristling with suspicious-looking proteins, that release can be dramatic.
That is precision medicine doing exactly what it promises: instead of treating every colon cancer the same way, the treatment is matched to the tumor’s biology. For families facing a Stage III dMMR diagnosis, October 8 was the day the odds got measurably better.
Be First to Comment